Logo image of ERA.PA

ERAMET (ERA.PA) Stock Fundamental Analysis

EPA:ERA - Euronext Paris - Matif - FR0000131757 - Common Stock - Currency: EUR

52.9  +1.15 (+2.22%)

Fundamental Rating

3

Overall ERA gets a fundamental rating of 3 out of 10. We evaluated ERA against 40 industry peers in the Metals & Mining industry. There are concerns on the financial health of ERA while its profitability can be described as average. ERA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year ERA was profitable.
ERA had a negative operating cash flow in the past year.
Of the past 5 years ERA 4 years were profitable.
ERA had a positive operating cash flow in 4 of the past 5 years.
ERA.PA Yearly Net Income VS EBIT VS OCF VS FCFERA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

ERA's Return On Assets of 0.22% is on the low side compared to the rest of the industry. ERA is outperformed by 60.00% of its industry peers.
Looking at the Return On Equity, with a value of 0.97%, ERA is doing worse than 60.00% of the companies in the same industry.
With a Return On Invested Capital value of 1.39%, ERA is not doing good in the industry: 65.00% of the companies in the same industry are doing better.
The Average Return On Invested Capital over the past 3 years for ERA is in line with the industry average of 7.42%.
The last Return On Invested Capital (1.39%) for ERA is well below the 3 year average (7.61%), which needs to be investigated, but indicates that ERA had better years and this may not be a problem.
Industry RankSector Rank
ROA 0.22%
ROE 0.97%
ROIC 1.39%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.61%
ROIC(5y)8.07%
ERA.PA Yearly ROA, ROE, ROICERA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

ERA has a Profit Margin of 0.48%. This is comparable to the rest of the industry: ERA outperforms 42.50% of its industry peers.
In the last couple of years the Profit Margin of ERA has declined.
ERA's Operating Margin of 3.27% is on the low side compared to the rest of the industry. ERA is outperformed by 60.00% of its industry peers.
In the last couple of years the Operating Margin of ERA has declined.
ERA has a better Gross Margin (66.89%) than 87.50% of its industry peers.
ERA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 3.27%
PM (TTM) 0.48%
GM 66.89%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ERA.PA Yearly Profit, Operating, Gross MarginsERA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ERA is destroying value.
Compared to 1 year ago, ERA has more shares outstanding
The number of shares outstanding for ERA has been increased compared to 5 years ago.
ERA has a better debt/assets ratio than last year.
ERA.PA Yearly Shares OutstandingERA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ERA.PA Yearly Total Debt VS Total AssetsERA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.14, we must say that ERA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ERA (1.14) is worse than 72.50% of its industry peers.
A Debt/Equity ratio of 1.35 is on the high side and indicates that ERA has dependencies on debt financing.
ERA has a worse Debt to Equity ratio (1.35) than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z 1.14
ROIC/WACC0.15
WACC9.37%
ERA.PA Yearly LT Debt VS Equity VS FCFERA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 1.64 indicates that ERA should not have too much problems paying its short term obligations.
ERA's Current ratio of 1.64 is in line compared to the rest of the industry. ERA outperforms 42.50% of its industry peers.
ERA has a Quick Ratio of 1.17. This is a normal value and indicates that ERA is financially healthy and should not expect problems in meeting its short term obligations.
ERA's Quick ratio of 1.17 is fine compared to the rest of the industry. ERA outperforms 72.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 1.17
ERA.PA Yearly Current Assets VS Current LiabilitesERA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

3

3. Growth

3.1 Past

ERA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.47%.
The earnings per share for ERA have been decreasing by -64.00% on average. This is quite bad
ERA shows a decrease in Revenue. In the last year, the revenue decreased by -9.78%.
ERA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.
EPS 1Y (TTM)-88.47%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%406.32%
Revenue 1Y (TTM)-9.78%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-10.08%

3.2 Future

The Earnings Per Share is expected to grow by 31.30% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 5.55% on average over the next years.
EPS Next Y-57.76%
EPS Next 2Y8.24%
EPS Next 3Y31.3%
EPS Next 5YN/A
Revenue Next Year5.37%
Revenue Next 2Y8.73%
Revenue Next 3Y5.55%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ERA.PA Yearly Revenue VS EstimatesERA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B 5B
ERA.PA Yearly EPS VS EstimatesERA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 10 20 30

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 123.02, ERA can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ERA is valued a bit more expensive than the industry average as 62.50% of the companies are valued more cheaply.
ERA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.50.
The Price/Forward Earnings ratio is 29.84, which means the current valuation is very expensive for ERA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ERA indicates a slightly more expensive valuation: ERA is more expensive than 70.00% of the companies listed in the same industry.
ERA is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 123.02
Fwd PE 29.84
ERA.PA Price Earnings VS Forward Price EarningsERA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

ERA's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.92
ERA.PA Per share dataERA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

ERA's earnings are expected to grow with 31.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.24%
EPS Next 3Y31.3%

2

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.66%, ERA has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.08, ERA pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.35, ERA has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.66%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
ERA.PA Yearly Dividends per shareERA.PA Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 2025 1 2 3

5.3 Sustainability

307.14% of the earnings are spent on dividend by ERA. This is not a sustainable payout ratio.
DP307.14%
EPS Next 2Y8.24%
EPS Next 3Y31.3%
ERA.PA Yearly Income VS Free CF VS DividendERA.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M
ERA.PA Dividend Payout.ERA.PA Dividend Payout, showing the Payout Ratio.ERA.PA Dividend Payout.PayoutRetained Earnings

ERAMET

EPA:ERA (7/18/2025, 7:00:00 PM)

52.9

+1.15 (+2.22%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)04-24 2025-04-24
Earnings (Next)07-30 2025-07-30
Inst Owners11.85%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.52B
Analysts55
Price Target61.03 (15.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.66%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP307.14%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.28%
PT rev (3m)-28.2%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-39.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.63%
Valuation
Industry RankSector Rank
PE 123.02
Fwd PE 29.84
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.52
EV/EBITDA 9.92
EPS(TTM)0.43
EY0.81%
EPS(NY)1.77
Fwd EY3.35%
FCF(TTM)-28.23
FCFYN/A
OCF(TTM)-4.35
OCFYN/A
SpS101.98
BVpS50.1
TBVpS34.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.22%
ROE 0.97%
ROCE 1.92%
ROIC 1.39%
ROICexc 1.7%
ROICexgc 1.9%
OM 3.27%
PM (TTM) 0.48%
GM 66.89%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.61%
ROIC(5y)8.07%
ROICexc(3y)11.46%
ROICexc(5y)11.88%
ROICexgc(3y)13.48%
ROICexgc(5y)14.02%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexcg growth 3Y-56.22%
ROICexcg growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA 7.9
Cap/Depr 454.97%
Cap/Sales 23.42%
Interest Coverage 0.56
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 1.17
Altman-Z 1.14
F-Score2
WACC9.37%
ROIC/WACC0.15
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.47%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%406.32%
EPS Next Y-57.76%
EPS Next 2Y8.24%
EPS Next 3Y31.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.78%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-10.08%
Revenue Next Year5.37%
Revenue Next 2Y8.73%
Revenue Next 3Y5.55%
Revenue Next 5YN/A
EBIT growth 1Y-23.81%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year104.71%
EBIT Next 3Y37.27%
EBIT Next 5YN/A
FCF growth 1Y-61.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.27%
OCF growth 3YN/A
OCF growth 5YN/A